Royal Bank of Canada
BTAI icon

Royal Bank of Canada’s BioXcel Therapeutics BTAI Stock Holding History

Royal Bank of Canada’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-79
Closed -$2K – 6882
2024
Q2 		$2K Sell
79
-11
-12% -$368 ﹤0.01% 6710
2024
Q1 		$4K Sell
90
-327
-78% -$15.6K ﹤0.01% 6487
2023
Q4 		$19K Buy
417
+226
+118% +$12.6K ﹤0.01% 6323
2023
Q3 		$7K Buy
191
+72
+61% +$7.28K ﹤0.01% 6519
2023
Q2 		$13K Buy
119
+18
+18% +$5.99K ﹤0.01% 6371
2023
Q1 		$29K Sell
101
-68
-40% -$29K ﹤0.01% 5879
2022
Q4 		$57K Buy
169
+122
+260% +$29.5K ﹤0.01% 5797
2022
Q3 		$9K Buy
47
+4
+9% +$929 ﹤0.01% 6465
2022
Q2 		$9K Sell
43
-25
-37% -$5.26K ﹤0.01% 6417
2022
Q1 		$22K Sell
68
-167
-71% -$48.4K ﹤0.01% 6547
2021
Q4 		$76K Sell
235
-180
-43% -$77.2K ﹤0.01% 6121
2021
Q3 		$202K Buy
415
+41
+11% +$18K ﹤0.01% 5162
2021
Q2 		$174K Sell
374
-89
-19% -$48.5K ﹤0.01% 5197
2021
Q1 		$320K Buy
463
+105
+29% +$84.5K ﹤0.01% 4558
2020
Q4 		$265K Buy
358
+179
+100% +$139K ﹤0.01% 4647
2020
Q3 		$124K Buy
179
+100
+127% +$75.1K ﹤0.01% 4854
2020
Q2 		$67K Buy
79
+76
+2,533% +$49.6K ﹤0.01% 5074
2020
Q1 		$1K Sell
3
-23
-88% -$8.27K ﹤0.01% 6403
2019
Q4 		$6K Buy
+26
New +$2.61K ﹤0.01% 6287
2019
Q3 		– Sell
-6
Closed -$946 – 6712
2019
Q2 		$1K Buy
+6
New +$1.02K ﹤0.01% 6678
2018
Q4 		– Sell
-1
Closed – – 6758
2018
Q3 		$0 Buy
+1
New +$148 ﹤0.01% 6720
2018
Q2 		– Sell
-150
Closed -$25K – 6515
2018
Q1 		$25K Buy
+150
New +$25K ﹤0.01% 5366

Other funds holding BTAI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Royal Bank of Canada's BTAI Position: Q3 2024 in Review

Royal Bank of Canada sold out of BioXcel Therapeutics (BTAI) in Q3 2024, closing a stake of 79 shares — an estimated $2K sold.

Royal Bank of Canada first reported a position in BTAI in Q1 2018 and held it in 22 quarters. The position peaked at $320K in Q1 2021. 49 funds tracked by Wall St. Rank hold BTAI as of Q3 2024.

  • Royal Bank of Canada reported no remaining BioXcel Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 79 BioXcel Therapeutics shares in Q3 2024, an estimated $2K.
  • Royal Bank of Canada first reported a position in BioXcel Therapeutics in Q1 2018 and held it in 22 quarters.
  • Royal Bank of Canada's BioXcel Therapeutics position peaked at $320K in Q1 2021.
  • 49 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2024.

Based on Royal Bank of Canada's 13F filing for Q3 2024, filed 14 Nov 2024.